McGill Alert / Alerte de McGill

Updated: Fri, 07/12/2024 - 12:16

McGill Alert. The downtown campus will remain partially closed through the evening of Monday, July 15. See the Campus Safety site for details.

Alerte de McGill. Le campus du centre-ville restera partiellement fermé jusqu’au lundi 15 juillet, en soirée. Complément d’information : Direction de la protection et de la prévention

Carlos Telleria

Carlos Telleria
Contact Information
Email address: 
carlos.telleria [at]
New therapeutic trial designs in personalized medicine: Molecular Oncology
Current research: 

Dr. Carlos Telleria is a reproductive endocrinologist whose research focuses on understanding the molecular mechanisms driving the physio-pathology of reproductive-related tissues. Dr. Telleria received his doctoral training from the National Council for Scientific and Technical Research (Conicet) of Argentina, and acquired postdoctoral expertise at the Department of Physiology, College of Medicine of the University of Illinois at Chicago. Before joining the Department of Pathology at McGill University, Dr. Telleria navigated the academic ranks at the Division of Biomedical Sciences of the Sanford School of Medicine of the University of South Dakota. During his years as an academic researcher Dr. Telleria mentored several undergraduate and graduate students, and received various awards for research and teaching excellence. Dr. Telleria is currently member of the editorial board of various peer review scientific journals, including Hormones and Cancer, Scientific Reports, Biology of Reproduction, Reproductive Biology and Endocrinology, and Cancer Growth and Metastasis.

The primary research interest in Dr. Telleria’s laboratory is in the field of ovarian cancer biology and preclinical therapy. Ovarian cancer is a deadly disease mostly because is diagnosed when the tumor has already invaded the peritoneal cavity. Diagnosed patients undergo surgery and platinum-based chemotherapy. This standard of care is initially effective, leading to disease remission for about two years in the standard responder. Ultimately, however, the disease recurs and no longer responds to previous therapy. Therefore, novel therapies for ovarian cancer are desperately needed. The overall approach in Dr. Telleria’s lab to develop new potential treatments for this disease is to consider that the time between remission and recurrence can be exploited by using a chronic intervention to maintain residual ovarian cancer cells, which had escaped initial therapy, in a non-proliferative or dormant status, and/or prevent their awakening. Within this scope, current investigations are tailored to understand the pathobiology of ovarian cancer within the microenvironment of the peritoneal cavity, to study the molecular mechanisms driving dormancy of cancer cells that had survived chemotherapy, and to exploit protein homeostasis to develop therapies for non-dividing cancer cells.

Back to top